Continuous Glucose Monitor (CGM): "Normal" Lab Range vs. Functional Optimal

What a CGM Actually Measures (and Why It Differs from a Fasting Draw)

A continuous glucose monitor reads interstitial fluid glucose every 1 to 5 minutes through a subcutaneous filament, producing up to 288 data points per day. A fasting blood draw, by contrast, captures a single snapshot. That distinction matters because glucose is not static. It oscillates in response to meals, stress hormones, sleep quality, and physical activity.

The sensor measures interstitial glucose, not plasma glucose directly. Interstitial readings lag venous blood by roughly 5 to 15 minutes, a delay that increases during rapid glucose changes. Current-generation devices like the Dexcom G7 and Abbott FreeStyle Libre 3 report a mean absolute relative difference (MARD) of 8.5% to 9.2%, meaning sensor values track venous glucose closely but not identically. For clinical decisions such as medication adjustments, confirmatory fingerstick or lab values remain the standard. For pattern recognition, CGM data is far superior to any static lab.

The American Diabetes Association (ADA) Standards of Care 2024 endorse CGM-derived metrics, including time in range (TIR), time below range (TBR), and glucose management indicator (GMI), as valid clinical endpoints. These metrics correlate strongly with A1c but provide granularity that A1c cannot: an A1c of 6.0% might reflect stable glucose around 126 mg/dL or wild swings between 60 and 200 mg/dL. Only CGM separates those two scenarios.

The Standard "Normal" Reference Range: Where It Comes From

The ADA defines normal fasting plasma glucose as below 100 mg/dL, prediabetes as 100 to 125 mg/dL, and diabetes as 126 mg/dL or above on two separate occasions. These cutoffs descend from epidemiological studies correlating fasting glucose with retinopathy risk, specifically the threshold at which microvascular damage becomes statistically detectable.

The problem is timing. Retinopathy-based cutoffs identify disease after years of metabolic deterioration. A 2020 cohort analysis published in The Lancet found that individuals with fasting glucose between 95 and 99 mg/dL (still "normal") had a 2.3-fold higher 10-year risk of developing type 2 diabetes compared to those below 85 mg/dL. The standard range tells you whether you have crossed a line. It does not tell you how fast you are approaching it.

CGM-based population data adds another layer. A study of 153 non-diabetic adults wearing CGMs for 2 to 4 weeks found a mean sensor glucose of approximately 99 mg/dL, with 96% of readings falling between 70 and 140 mg/dL. Some participants classified as "normal" by fasting labs spent significant time above 140 mg/dL after meals, a pattern invisible on standard testing. The conventional range is not wrong. It is incomplete.

Functional Optimal Ranges: What the Research Supports

Functional or optimal glucose targets are not standardized by any single guideline body. They come from synthesizing prospective cohort data, CGM population studies, and cardiovascular risk curves. Here is what the evidence supports for non-diabetic adults pursuing metabolic optimization.

Fasting glucose: 72 to 89 mg/dL. The lower end of the conventional range tracks with the lowest cardiovascular and diabetes risk in multiple cohorts. A meta-analysis in the European Heart Journal found that fasting glucose above 90 mg/dL, still well within "normal," was associated with incrementally higher cardiovascular mortality.

Post-meal peak: below 140 mg/dL, ideally below 120 mg/dL, returning to baseline within 2 hours. The International Diabetes Federation post-meal glucose guideline recommends that post-prandial glucose in non-diabetic individuals should not exceed 140 mg/dL. Some endocrinologists targeting metabolic optimization aim for a tighter ceiling of 120 mg/dL, though this threshold is based on expert consensus rather than randomized trial data.

Time in range (70 to 140 mg/dL): above 90% for non-diabetic individuals. The 2022 international consensus on CGM metrics established TIR above 70% as the target for people with diabetes. For those without diabetes, a TIR above 90% reflects glucose patterns consistent with low metabolic risk.

Coefficient of variation (CV): below 33%. CV measures glucose variability independent of mean glucose. A CV above 36% is associated with increased hypoglycemia risk and, in emerging data, with higher oxidative stress markers. The consensus target of below 33% applies across populations.

GMI: below 5.7%. The glucose management indicator estimates what an A1c would be based on mean sensor glucose. A GMI below 5.7% corresponds to a mean glucose below approximately 117 mg/dL, aligning with the non-prediabetic range.

Why "Normal" Glucose Can Still Signal Metabolic Dysfunction

A fasting glucose of 96 mg/dL earns a "normal" flag on every standard lab report. But pair that number with CGM data showing post-meal spikes to 175 mg/dL, a coefficient of variation of 38%, and time above 140 mg/dL exceeding 8% of the day, and the metabolic picture looks different.

This discrepancy exists because fasting glucose is a lagging indicator. Insulin resistance develops gradually: pancreatic beta cells compensate by producing more insulin, keeping fasting glucose within range for years while post-meal excursions quietly worsen. A 2018 Stanford study using CGMs on 57 non-diabetic participants identified "glucotypes," distinct patterns of glucose variability. Some participants with normal A1c values exhibited glucose excursions into the prediabetic and diabetic range after standardized meals. This finding does not mean these individuals have diabetes. It means their glucose regulation is under strain in ways a fasting draw cannot detect.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, has noted: "A1c is a blunt instrument. CGM gives us a much more nuanced picture of what is happening with glucose throughout the day, and that matters for both people with diabetes and those trying to prevent it."

The practical concern: post-meal hyperglycemia above 140 mg/dL triggers endothelial dysfunction and oxidative stress even in non-diabetic individuals, according to data published in Diabetes Care. Repeated spikes may contribute to vascular risk before any conventional lab value trips an alarm.

Key CGM Metrics and What Each Tells You

Understanding CGM output requires familiarity with five core metrics. Each captures a different dimension of glucose behavior.

Mean glucose is the arithmetic average of all sensor readings over a defined period, typically 14 days. It correlates with A1c but is more responsive to short-term changes. A mean glucose of 100 mg/dL corresponds roughly to an A1c of 5.1%.

Time in range (TIR) quantifies the percentage of readings between 70 and 140 mg/dL (for non-diabetic targets) or 70 and 180 mg/dL (the consensus diabetes target). Each 5% increase in TIR corresponds to a roughly 0.5% decrease in A1c, per the DCCT/EDIC dataset reanalysis.

Time below range (TBR) captures readings under 70 mg/dL (level 1 hypoglycemia) or under 54 mg/dL (level 2, clinically significant). For non-diabetic individuals not on glucose-lowering medication, TBR should be below 1%. Recurrent hypoglycemia on CGM may indicate reactive hypoglycemia, adrenal insufficiency, or insulinoma and warrants medical evaluation.

Coefficient of variation (CV) equals standard deviation divided by mean glucose, expressed as a percentage. Below 33% indicates stable glucose. Above 36% is considered unstable. CV matters because two people with identical mean glucose can have radically different metabolic profiles: one flat, one oscillating. The oscillating pattern correlates with worse outcomes in observational data from Diabetes Technology & Therapeutics.

Glucose management indicator (GMI) translates mean sensor glucose into an estimated A1c. It is useful for tracking trends between lab draws, though it may diverge from measured A1c due to differences in red blood cell lifespan and hemoglobin glycation rates.

How to Move Your CGM Readings Toward Optimal

Shifting from "normal" to optimal on a CGM centers on reducing post-meal spikes, lowering glycemic variability, and maintaining fasting glucose at the lower end of the reference range. The following strategies have direct CGM evidence.

Meal composition and order. Eating protein and fiber before carbohydrates reduces glucose spikes by 30% to 40%, per a 2015 study in Diabetes Care. A CGM makes this effect visible in real time, allowing individuals to test personal responses. White rice may spike one person to 165 mg/dL and another to 120 mg/dL. The monitor shows which foods and sequences work.

Post-meal movement. A 15-minute walk after eating reduces peak glucose by an average of 22%, according to research in Sports Medicine. Walking within 30 minutes of finishing a meal captures the greatest effect. Even standing or light stretching outperforms sitting.

Sleep quality. A single night of restricted sleep (4 hours vs. 8 hours) increases next-day glucose responses by 15% to 20% in controlled studies. CGM data typically shows higher fasting glucose and greater post-meal variability after poor sleep. The AACE 2023 clinical practice guideline on obesity lists sleep optimization as a first-line metabolic intervention.

Stress and cortisol. Cortisol directly stimulates hepatic glucose output. CGM users often observe morning glucose rises (the "dawn phenomenon") and stress-related spikes unrelated to food. Chronic psychological stress can raise mean glucose by 5 to 15 mg/dL even without dietary changes.

Alcohol. Alcohol suppresses hepatic gluconeogenesis, and CGM data commonly shows delayed hypoglycemia 6 to 12 hours after consumption. Red wine with dinner may flatten the post-meal spike acutely but produce a nocturnal dip to 55 mg/dL. Monitoring reveals these patterns before they become symptomatic.

When a CGM Is Clinically Indicated vs. Elective

Insurance coverage for CGMs currently requires a diabetes diagnosis and, in many cases, insulin use. The FDA cleared the Dexcom G7 and Libre 3 for prescription use in people with diabetes. The Dexcom Stelo and Abbott Libre Rio received over-the-counter clearance in 2024 for adults 18 and older without insulin-dependent diabetes, a regulatory shift that opened CGM access to non-diabetic users.

Clinical indications supported by guidelines include type 1 and type 2 diabetes (particularly insulin-treated), gestational diabetes with glucose excursions, and prediabetes with difficulty achieving glycemic targets. The Endocrine Society's 2023 clinical practice guideline recommends CGM for all adults with type 1 diabetes and for type 2 diabetes patients on intensive insulin therapy, noting that CGM reduces A1c by an average of 0.4% and increases time in range by 1.5 to 2.5 hours per day.

Elective use in metabolically healthy individuals is growing but not guideline-endorsed. The rationale rests on behavior change: seeing real-time glucose responses to food, sleep, and exercise produces measurable dietary modifications in pilot data from the Journal of Clinical Endocrinology & Metabolism. Whether those short-term changes persist or reduce hard outcomes (cardiovascular events, diabetes incidence) remains unproven in randomized trials.

Dr. Anne Peters, Professor of Clinical Medicine at USC Keck School of Medicine, has stated: "CGM for people without diabetes is like a Fitbit for glucose. It gives you data, and data can motivate behavior change. But we need long-term studies to know if it changes outcomes."

Interpreting Your CGM Report: A Practical Walkthrough

A standard 14-day CGM report includes an ambulatory glucose profile (AGP), a time-in-range summary, and daily overlay graphs. Read them in this order.

Start with the TIR bar. If time in the 70 to 140 mg/dL range is above 90% and TBR is below 1%, overall glycemic control is strong. Next, check CV. If it is below 33%, variability is acceptable. If TIR is high but CV is above 36%, you may have frequent moderate swings that average out.

Move to the AGP. The median line shows your typical glucose trajectory over 24 hours. The interquartile range (shaded band) shows where 50% of your readings fall. A narrow band means predictable glucose. A wide band, especially after meals or overnight, indicates inconsistency worth investigating.

Look at daily overlays to identify specific triggers. A spike every day at 1 PM probably correlates with lunch composition. A rise at 4 AM (dawn phenomenon) reflects cortisol-driven hepatic output and is generally not actionable through diet alone.

Compare your GMI to your most recent lab A1c. A GMI lower than lab A1c by more than 0.3% may indicate that your red blood cell turnover rate causes A1c to overestimate average glucose, information relevant for medication titration decisions your clinician should know about.

Limitations of CGM Data for Non-Diabetic Users

CGM data is powerful but not infallible. Sensor accuracy degrades in the first 24 hours after insertion and during rapid glucose changes. Compression lows, false readings caused by sleeping on the sensor arm, mimic hypoglycemia and can cause unnecessary alarm.

Interstitial glucose lags blood glucose by minutes. During intense exercise, CGM may show glucose dropping while venous glucose is already recovering. This lag matters less for pattern recognition over days and more for acute, real-time decision-making.

For non-diabetic individuals, the biggest risk is over-interpretation. A single post-meal spike to 155 mg/dL does not indicate pathology. The ADA consensus report on CGM metrics emphasizes trends over individual readings. Patterns across 14 days matter. Isolated excursions do not.

Cost is a practical barrier. Over-the-counter CGMs (Stelo, Libre Rio) run $75 to $99 per month without insurance. Prescription CGMs cost $200 to $400 monthly without coverage. For individuals without diabetes, this represents an out-of-pocket wellness expense with no established return-on-investment in terms of hard clinical endpoints, at least not yet.

Non-diabetic CGM users should review data with a clinician rather than self-diagnosing based on glucose patterns. A fasting glucose consistently at 56 mg/dL on CGM requires investigation, not a dietary tweak.